Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Featured Stories


Lilly’s Diabetes Franchise Poised For A Shakeup As Conterno Steps Down

Lilly’s newer diabetes drugs are selling well, although Trulicity numbers disappointed analysts, and are among the firm’s growth-drivers. Longtime diabetes head Enrique Conterno will be succeeded by insider Mike Mason.

Sales & Earnings Business Strategies Companies

Alkermes Restructures, Prioritizing CNS And Oncology And Cutting 160 Employees

The reorganization, which is expected to save $150m, will cement the company's transition from a drug delivery specialist to a drug developer, CEO Richard Pops said.

Business Strategies Sales & Earnings Research and Development Strategies

Podcast: Woodford’s UK Biotech Fallout, Rare Disease Deals and Brexit

Scrip's Kevin Grogan and Andrew McConaghie try out the padded cell/recording studio at Informa HQ in London, giving their take on three hot topics from biopharma and healthcare.

Brexit Rare Diseases Deals

Spotlight On APAC

'Buy China' In Procurement Schemes - Should You Worry?

A recent trade group report points to a rising and alarming "Buy China" trend in procurement rounds in the country. Although largely in medical device bidding, it may potentially affect the pharma sector, an analysis from the recent “4+7” centralized bidding scheme show.

China Commercial

Advertisement


 Recent Tweets from Scrip


Advertisement

 

Commercial Explore this Topic

Set Alert for Commercial

Takeda Adds Celiac Disease Candidate To GI Efforts

Takeda has exercised an option on partner Cour Pharmaceutical’s first-in-class lead product, after a positive Phase IIa study showed, for the first time, it was possible to induce specific immune tolerance to a foreign antigen in an autoimmune disease.

 


 

Deals Gastrointestinal

Buying Encycle Gives Zealand Its First External Asset

Acquiring Encycle Therapeutics brings Zealand Pharma a promising IBD asset and expands the breadth of its peptide discovery platform.

Deals Gastrointestinal

Bavarian Nordic Transformed By GSK Vaccines Buy

Buying two vaccines for rabies and tick-borne encephalitis complements the recently approved smallpox and monkeypox vaccine Jynneos. Now the Danish firm needs to start selling them.

Vaccines Deals

Novartis Adds To NASH Pipeline By Licensing Pliant’s Integrin Inhibitor

Deal for preclinical asset adds an anti-fibrotic mechanism to Novartis’ NASH program. Pliant produced preclinical data showing strong anti-fibrotic effect.

Deals Research and Development Strategies

An About Face As Biogen Says It Will File Aducanumab In Alzheimer’s

Biogen surprised investors with news that it will file aducanumab with the FDA based on data from more patients treated at the highest dose than in the interim futility analysis that led to termination of two Phase III studies in March.

Clinical Trials Research and Development Strategies

An Early Surprise Win For BMS’s Opdivo/Yervoy In Lung Cancer

CheckMate-9LA testing nivolumab plus ipilimumab plus chemo was stopped early due to a survival win. The promise of another foothold in first-line lung cancer could buoy investors ahead of what could be disappointing Q3 sales.

Clinical Trials ImmunoOncology
See All

Policy & Regulation Explore this Topic

Set Alert for Policy & Regulation

AstraZeneca’s Farxiga Approval In Heart Failure A First For SGLT2 Inhibitors

Farxiga, with a new indication to prevent hospitalization for heart failure in type 2 diabetes patients, is the first drug among the SGLT2 class to gain this indication outside of diabetics with renal disease.

Approvals Cardiovascular

J&J's Spravato Set For EU Launches Soon

If the nasal spray is approved by the European Commission, seven months after getting the green light in the US, Spravato will offer the first new mechanism of action in 30 years to treat major depressive disorder.
Neurology Drug Review

Kiadis Crushed By EMA Rejection Of T-Cell Therapy

The Dutch company's dataset on its stem cell transplant adjunct ATIR101 is not enough to satisfy European regulators as the standard of care in post-transplant patients has changed since the original filing.
Clinical Trials Drug Review
See All

Research & Development Explore this Topic

Set Alert for Research & Development

Alzheimer’s Biomarker Benefit From Failed Janssen BACE Inhibitor?

New access agreement for samples from failed clinical trial to support identification of valuable new biomarkers, and possibly novel drugs, in highly challenging disorder.

Research & Development Neurology

An Early Surprise Win For BMS’s Opdivo/Yervoy In Lung Cancer

CheckMate-9LA testing nivolumab plus ipilimumab plus chemo was stopped early due to a survival win. The promise of another foothold in first-line lung cancer could buoy investors ahead of what could be disappointing Q3 sales.

Clinical Trials ImmunoOncology

Novartis’s Fevipiprant Hit By Phase III Asthma Failure

Novartis’s investigational oral therapy for asthma fell at the first Phase III hurdle but pivotal studies in severe disease will be key to prospects.

Respiratory Clinical Trials
See All
UsernamePublicRestriction

Register

Advertisement